Blood Test Could Show Womens' Risks

Photo: Woman with baby

Postnatal depression normally
starts around two weeks after
childbirth; ©
Lev Dolgatshjov

Presenting the research Professor Dimitris Grammatopoulos at the University of Warwick, said that approximately one in seven women who give birth suffer from PND, which normally starts around two weeks after childbirth.

He explained: “Current screening policies rely on the opportunistic finding of PND cases using screening tools such as the Edinburgh Postnatal Depression Score (EPDS), but such tests cannot identify women at risk, ahead of them developing the condition."

The researchers assessed a group of 200 pregnant women for PND using the EPDS, once during their first visit to the ante-natal clinic, and again two to eight weeks after they had given birth. They found that the women who developed PND were more likely to have specific genetic variants of the bcl1 and rs242939 single nucleotide polymorphisms (SNPs)[2] of the glucocorticoid receptor and the corticotrophin-releasing hormone receptor-1 genes, respectively.

These receptors control the activity of the hypothalamo-pituitary adrenal (HPA) axis - an endocrine system that is activated in response to stress. The hypothalamus is part of the brain that monitors many aspects of the state of the body’s systems and is closely linked with the pituitary gland, which releases a number of hormones into the blood stream that control vital body functions.

The finding appears to show that postnatal depression is a specific subgroup of depression with a distinct genetic element which means that some women are genetically more reactive to the environmental factors which trigger depression.

“Although we knew already that there was an association of the HPA axis with depression, ours is the first study to show a link between specific elements of this pathway and the particular case of PND,” said Grammatopoulos.

“We now intend to conduct further research on other genetic variants of the HPA axis in a larger, multi-centre study involving women from Coventry, Birmingham, and London. We think that we have made an important step forward in characterising the prospective risks and are therefore paving the way for timely, appropriate medical treatment for women who are likely to develop PND.”; Source: University of Warwick